Introduction: Fabry disease is a rare metabolic, multisystemic, and X-linked lysosomal storage disorder. The involvement of the autonomic nervous system is well defined; however, data on the variability of the blood pressure (BP) and heart rate in Fabry disease are largely missing. In this study, we aimed to examine the circadian variations of BP and heart rate variability in Fabry disease patients. Methods: We recruited 31 consecutive adult (age >18 years) Fabry disease patients (16 males and 15 females) who were regularly followed up in our outpatient clinic between July 2019 and March 2020. We performed ambulatory blood pressure monitoring and echocardiography in all patients. We used standard deviation (SD), coefficient of variation (CV), and average real variability as the measures of variability. We constructed 2 control groups for propensity score matching using age, sex, and eGFR parameters in the first group and adding antihypertensive drug use to the above parameters in the second group. Results: All BP measurements were significantly lower in the FD group compared to that of the control groups, except the nighttime systolic BP. Regarding nondipping and reverse dipping statuses, FD patients and controls were similar. We found that none of the BP variability measures were higher in FD patients. Regarding heart rate variability data, both the nighttime SD and CV were significantly lower in FD patients compared to those of the controls. Conclusion: A decrease in heart rate variability, rather than an increase in BP variability, might be an early marker of autonomic involvement in FD.

1.
Desnick
RJ
,
Ioannou
YA
,
Eng
CM
.
α-galactosidase a deficiency: Fabry disease
. In:
Scriver
CR
,
Beaudet
AL
,
Sly
WS
,
Valle
D
, editors.
The metabolic and molecular bases of inherited diseases
. 7th ed.
New York
:
McGraw-Hill
;
1995
. p.
2741
84
.
2.
Mehta
A
,
Clarke
JT
,
Giugliani
R
,
Elliott
P
,
Linhart
A
,
Beck
M
,
Natural course of Fabry disease: changing pattern of causes of death in FOS–Fabry Outcome Survey
.
J Med Genet
.
2009 Aug
;
46
(
8
):
548
52
.
3.
Germain
DP
.
Fabry disease
.
Orphanet J Rare Dis
.
2010 Nov 22
;
5
(
1
):
30
. .
4.
Cable
WJ
,
Kolodny
EH
,
Adams
RD
.
Fabry disease: impaired autonomic function
.
Neurology
.
1982 May
;
32
(
5
):
498
502
. .
5.
Dutsch
M
,
Marthol
H
,
Stemper
B
,
Brys
M
,
Haendl
T
,
Hilz
MJ
.
Small fiber dysfunction predominates in Fabry neuropathy
.
J Clin Neurophysiol
.
2002
;
19
(
6
):
575
86
.
6.
Keshav
S
.
Gastrointestinal manifestations of Fabry disease
. In:
Mehta
A
,
Beck
M
,
Sunder-Plassmann
G
, editors.
Fabry disease: perspectives from 5 years of FOS
.
Oxford
:
Oxford PharmaGenesis
;
2006
. Chapter 28.
7.
Salviati
A
,
Burlina
AP
,
Borsini
W
.
Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy
.
Neurol Sci
.
2010 Jun
;
31
(
3
):
299
306
. .
8.
Rombach
SM
,
Twickler
TB
,
Aerts
JM
,
Linthorst
GE
,
Wijburg
FA
,
Hollak
CE
.
Vasculopathy in patients with fabry disease: current controversies and research directions
.
Mol Genet Metab
.
2010
;
99
(
2
):
99
108
. .
9.
Hilz
MJ
,
Marthol
H
,
Schwab
S
,
Kolodny
EH
,
Brys
M
,
Stemper
B
.
Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients
.
J Hypertens
.
2010 Jul
;
28
(
7
):
1438
48
. .
10.
Burlina
AP
,
Sims
KB
,
Politei
JM
,
Bennett
GJ
,
Baron
R
,
Sommer
C
,
Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel
.
BMC Neurol
.
2011 May 27
;
11
:
61
.
11.
Spallone
V
.
Blood pressure variability and autonomic dysfunction
.
Curr Diab Rep
.
2018 Oct 25
;
18
(
12
):
137
. .
12.
Scuteri
A
,
Morrell
CH
,
Orru
M
,
AlGhatrif
M
,
Saba
PS
,
Terracciano
A
,
Gender specific profiles of white coat and masked hypertension impacts on arterial structure and function in the SardiNIA study
.
Int J Cardiol
.
2016
;
217
:
92
8
.
13.
Nilsson
PM
,
Laurent
S
,
Cunha
PG
,
Olsen
MH
,
Rietzschel
E
,
Franco
OH
,
Characteristics of healthy vascular ageing in pooled population-based cohort studies: the global metabolic syndrome and Artery REsearch Consortium
.
J Hypertens
.
2018
;
36
(
12
):
2340
9
.
14.
Di Daniele
N
,
Fegatelli
DA
,
Rovella
V
,
Castagnola
V
,
Gabriele
M
,
Scuteri
A
.
Circadian blood pressure patterns and blood pressure control in patients with chronic kidney disease
.
Atherosclerosis
.
2017
;
267
:
139
45
. .
15.
Scuteri
A
,
Rovella
V
,
Alunni Fegatelli
D
,
Tesauro
M
,
Gabriele
M
,
Di Daniele
N
.
An operational definition of SHATS (Systemic Hemodynamic Atherosclerotic Syndrome): role of arterial stiffness and blood pressure variability in elderly hypertensive subjects
.
Int J Cardiol
.
2018
;
263
:
132
7
. .
16.
Scuteri
A
,
Wang
H
.
Pulse wave velocity as a marker of cognitive impairment in the elderly
.
J Alzheimers Dis
.
2014
;
42 Suppl 4
:
S401
10
. .
17.
Scuteri
A
,
Benetos
A
,
Sierra
C
,
Coca
A
,
Chicherio
C
,
Frisoni
GB
,
Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: why and how-a decision-making support from the working group on “hypertension and the brain” of the European Society of Hypertension and from the European Geriatric Medicine Society
.
J Hypertens
.
2021
;
39
(
1
):
90
100
.
18.
Levey
AS
,
Stevens
LA
,
Schmid
CH
,
Zhang
YL
,
Castro
AF
,
Feldman
HI
,
A new equation to estimate glomerular filtration rate
.
Ann Intern Med
.
2009 May 5
;
150
(
9
):
604
12
.
19.
Verdecchia
P
,
Schillaci
G
,
Porcellati
C
.
Dippers versus non-dippers
.
J Hypertens Suppl
.
1991 Dec
;
9
(
8
):
S42
4
.
20.
Williams
B
,
Mancia
G
,
Spiering
W
,
Agabiti Rosei
E
,
Azizi
M
,
Burnier
M
,
ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)
.
Eur Heart J
.
2018 Sep 1
;
39
(
33
):
3021
104
.
21.
Devereux
RB
,
Alonso
DR
,
Lutas
EM
,
Gottlieb
GJ
,
Campo
E
,
Sachs
I
,
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings
.
Am J Cardiol
.
1986 Feb 15
;
57
(
6
):
450
8
.
22.
Devereux
RB
,
Lutas
EM
,
Casale
PN
,
Kligfield
P
,
Eisenberg
RR
,
Hammond
IW
,
Standardization of M-mode echocardiographic left ventricular anatomic measurements
.
J Am Coll Cardiol
.
1984 Dec
;
4
(
6
):
1222
30
.
23.
Nagueh
SF
,
Smiseth
OA
,
Appleton
CP
,
Byrd
BF
,
Dokainish
H
,
Edvardsen
T
,
Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
.
Eur Heart J Cardiovasc Imaging
.
2016 Dec
;
17
(
12
):
1321
60
.
24.
Armstrong
WF
,
Thomas
R
.
Feigenbaum’s echocardiography
. 7th ed.
Philadelphia
:
Lippincott Williams & Wilkins
;
2011
.
25.
Ortiz
A
,
Oliveira
JP
,
Waldek
S
,
Warnock
DG
,
Cianciaruso
B
,
Wanner
C
,
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy
.
Nephrol Dial Transplant
.
2008 May
;
23
(
5
):
1600
7
.
26.
Schiffmann
R
,
Warnock
DG
,
Banikazemi
M
,
Bultas
J
,
Linthorst
GE
,
Packman
S
,
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
.
Nephrol Dial Transplant
.
2009 Jul
;
24
(
7
):
2102
11
.
27.
Branton
MH
,
Schiffmann
R
,
Sabnis
SG
,
Murray
GJ
,
Quirk
JM
,
Altarescu
G
,
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course
.
Medicine
.
2002
;
81
(
2
):
122
38
.
28.
Kleinert
J
,
Dehout
F
,
Schwarting
A
,
De Lorenzo
AG
,
Ricci
R
,
Kampmann
C
,
Prevalence of uncontrolled hypertension in patients with Fabry disease
.
Am J Hypertens
.
2006 Aug
;
19
(
8
):
782
7
.
29.
Rossi
F
,
Svarstad
E
,
Elsaid
H
,
Binaggia
A
,
Roggero
L
,
Auricchio
S
,
Elevated ambulatory blood pressure measurements are associated with a progressive form of Fabry disease
.
High Blood Press Cardiovasc Prev
.
2021
;
28
(
3
):
309
19
.
30.
Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology
.
Circulation
.
1996 Mar 1
;
93
(
5
):
1043
65
.
31.
Lodhi
HA
,
Peri‐Okonny
PA
,
Schesing
K
,
Phelps
K
,
Ngo
C
,
Evans
H
,
Usefulness of blood pressure variability indices derived from 24‐hour ambulatory blood pressure monitoring in detecting autonomic failure
.
J Am Heart Assoc
.
2019 Apr 2
;
8
(
7
):
e010161
.
32.
Dekker
JM
,
Crow
RS
,
Folsom
AR
,
Hannan
PJ
,
Liao
D
,
Swenne
CA
,
Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis risk in communities
.
Circulation
.
2000
;
102
(
11
):
1239
44
.
33.
Maciorowska
M
,
Krzesiński
P
,
Wierzbowski
R
,
Gielerak
G
.
Heart rate variability in patients with hypertension: the effect of metabolic syndrome and antihypertensive treatment
.
Cardiovasc Ther
.
2020
;
2020
:
8563135
. .
34.
Yamabe
M
,
Sanyal
SN
,
Miyamoto
S
,
Hadama
T
,
Isomoto
S
,
Ono
K
.
Three different bradycardic agents, zatebradine, diltiazem and propranolol, distinctly modify heart rate variability and QT-interval variability
.
Pharmacology
.
2007
;
80
(
4
):
293
303
. .
35.
Petretta
M
,
Canonico
V
,
Madrid
A
,
Mickiewicz
M
,
Spinelli
L
,
Marciano
F
,
Comparison of verapamil versus felodipine on heart rate variability in hypertensive patients
.
J Hypertens
.
1999
;
17
(
5
):
707
13
.
36.
Menezes Ada
S
 Jr
,
Moreira
HG
,
Daher
MT
.
Analysis of heart rate variability in hypertensive patients before and after treatment with angiotensin II-converting enzyme inhibitors
.
Arq Bras Cardiol
.
2004
;
83
(
2
):
1695
728
.
37.
Binkley
PF
,
Haas
GJ
,
Starling
RC
,
Nunziata
E
,
Hatton
PA
,
Leier
CV
,
Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure
.
J Am Coll Cardiol
.
1993
;
21
(
3
):
655
61
.
38.
Carthy
ER
.
Autonomic dysfunction in essential hypertension: a systematic review
.
Ann Med Surg
.
2014
;
3
(
1
):
2
7
. .
39.
Desai
MY
,
Watanabe
MA
,
Laddu
AA
,
Hauptman
PJ
.
Pharmacologic modulation of parasympathetic activity in heart failure
.
Heart Fail Rev
.
2011
;
16
(
2
):
179
93
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.